Literature DB >> 18946779

Adiponectin as a biomarker of systemic inflammatory response in smoker patients with stable and exacerbation phases of chronic obstructive pulmonary disease.

Sevin Kirdar1, Mukadder Serter, Emel Ceylan, Asli Gamze Sener, Tülay Kavak, Fisun Karadağ.   

Abstract

BACKGROUND AND
OBJECTIVE: Adiponectin is an adipose tissue-derived specific protein that has a role in energy homeostasis, that has a protective role against the development of insulin resistance and atherosclerosis and that exhibits anti-inflammatory properties. We investigated serum adiponectin as a biomarker of systemic inflammatory response and its relation with leptin, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and nitric oxide (NO) in chronic obstructive pulmonary disease (COPD) patients.
MATERIAL AND METHODS: We studied 36 male patients with COPD (15 stable and 21 exacerbated) and 17 age and sex-matched healthy subjects. The adiponectin and leptin levels were measured by enzyme-linked immunosorbent assay. Serum CRP levels were measured using the nephelometric method. ESR was determined using the Westergren method and NO by the cadmium reduction method.
RESULTS: Adiponectin levels in COPD patients were significantly higher than those in control subjects (p<0.001), whereas there were no differences in leptin or NO levels. Serum levels of CRP, ESR and adiponectin were significantly higher in the exacerbated COPD patients compared to the stable group (p<0.001, p = 0.033 and p = 0.024, respectively), whereas the differences in leptin and NO levels were not significant. Serum levels of adiponectin were not correlated with FEV(1), FEV(1)/FVC, dyspnoea score, BMI or other inflammatory parameters in the stable COPD group. CRP and ESR correlated negatively with FEV(1) in the stable COPD group.
CONCLUSIONS: Adiponectin may be a marker of low-grade systemic inflammatory response in COPD. A further rise in serum adiponectin in the exacerbation period denotes that this may also be a biomarker of the exacerbation phase as well as CRP and ESR.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18946779     DOI: 10.1080/00365510802474400

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  26 in total

Review 1.  Metabolic Syndrome and the Lung.

Authors:  Cynthia W Baffi; Lisa Wood; Daniel Winnica; Patrick J Strollo; Mark T Gladwin; Loretta G Que; Fernando Holguin
Journal:  Chest       Date:  2016-01-20       Impact factor: 9.410

Review 2.  Leptin, adiponectin and pulmonary diseases.

Authors:  Nour Ali Assad; Akshay Sood
Journal:  Biochimie       Date:  2012-03-14       Impact factor: 4.079

Review 3.  The evolving role of adiponectin as an additive biomarker in HFrEF.

Authors:  Tahnee Sente; Andreas Gevaert; An Van Berendoncks; Christiaan J Vrints; Vicky Y Hoymans
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 4.  The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease.

Authors:  Behzad Heidari
Journal:  Caspian J Intern Med       Date:  2012

5.  Serum C-reactive protein level and distribution in chronic obstructive pulmonary disease versus healthy controls: a case-control study from Iran.

Authors:  Alireza Firouzjahi; Mahmoud Monadi; Fatemeh Karimpoor; Behzad Heidari; Yahya Dankoob; Karim Hajian-Tilaki; Mokarraram Gorgani Firozjaii
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

Review 6.  Muscle dysfunction in chronic obstructive pulmonary disease: update on causes and biological findings.

Authors:  Joaquim Gea; Sergi Pascual; Carme Casadevall; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2015-10       Impact factor: 2.895

7.  Different forms of adiponectin reduce the apoptotic and damaging effect of cigarette smoke extract on human bronchial epithelial cells.

Authors:  Meng-Yu Cheng; Hu Liu; Tie-Mei Zhang; Jian-Ying Xu
Journal:  Exp Ther Med       Date:  2016-11-04       Impact factor: 2.447

Review 8.  Adiponectin in pulmonary disease and critically ill patients.

Authors:  P Garcia; A Sood
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

9.  Biomarkers Predictive of Exacerbations in the SPIROMICS and COPDGene Cohorts.

Authors:  Jason D Keene; Sean Jacobson; Katerina Kechris; Gregory L Kinney; Marilyn G Foreman; Claire M Doerschuk; Barry J Make; Jeffrey L Curtis; Stephen I Rennard; R Graham Barr; Eugene R Bleecker; Richard E Kanner; Eric C Kleerup; Nadia N Hansel; Prescott G Woodruff; MeiLan K Han; Robert Paine; Fernando J Martinez; Russell P Bowler; Wanda K O'Neal
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

Review 10.  Obesity, adipokines, and lung disease.

Authors:  Akshay Sood
Journal:  J Appl Physiol (1985)       Date:  2009-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.